Cytosorbents provides u.s. fda and health canada regulatory update for drugsorb-atr

Princeton, n.j. , july 2, 2025 /prnewswire/ -- cytosorbents corporation (nasdaq: ctso), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for drugsorb™-atr with the u.s. food and drug administration (fda) and health canada.
ATR Ratings Summary
ATR Quant Ranking